HER2/neu positive tumors appeared to be relatively resistant to chemotherapy and radiation treatment, none of these cases having a pathological complete or at least subtotal response in the corresponding resection specimens. This observation requires confirmation in large randomized controlled studies....
No significant association was found between HER2/neu expression and stage, age, sex, ploidy, histological type or subtype. Moreover, log rank test indicated that overall and event-free survival was not significantly different in HER2/neu positive and negative patients. These data suggest that ...
A HER2-positive cancer diagnosis means that the cancer is likely to grow and spread more quickly and is more likely to recur. HER2-targeted treatments such as trastuzumab, pertuzumab or lapatinib may be part of the treatment plan for patients with HER2-positive cancer. If your tumor is HER2-...
RESULTS: Five out of ten USC cell lines overexpressed Her2/neu by IHC and showed amplification of the c-erbB2 gene. High levels of Her2/neu ECD were found in supernatants of all FISH-positive tumours. In contrast, FISH-negative USC was negative for Her2/neu ECD shedding. Serum Her2/neu ...
ObjectivesTo detect amplification of the HER2/neu gene by means of fluorescence in situ hybridization (FISH) in a series of 13 salivary duct carcinomas
HER2/neu amplifica- tion is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371–1379. 42 Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER2 in gastric carcinoma: association with Topoi- somerase IIalpha gene amplification, intestinal type, poor prognosis...
Data are displayed as CV of the 2500 means per fixed number of cells or FOVs, respectively. Agreement between the ECD/ICD ratio generated by image analysis and the pathologist's (F.F.) assessment for loss of ECD (positive, intermediate, or negative) was visualized using box plots. Cohen'...
HER2/neu-positive breast cancer is less responsive to any type of endocrine treatment [29]; approximately one-half of HER2/neu-positive breast cancers are also ER-positive, and this breast cancer subgroup (luminal B) is thus more refractory to endocrine therapy – despite the ER-positive status...
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor- 2/neu-positive urothelial carcinoma: results of a multi- center phase II National Cancer Institute trial. J Clin Oncol 2007;25:2218–2224. 1119 Modern Pathology (2011) 24, 1111–1119 ...
Overexpression of HER2 or its mouse homolog Neu induce tumorigenesis when expressed in mouse mammary tissue, however these tumors fail to form if the HER3 gene is knocked out in these tissues8. Similarly, the transcriptional or shRNA knockdown of HER3 in HER2-amplified human cancer cell lines ...